Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemic area: A surveillance study  by Chang, Kuo-Chin et al.
Kaohsiung Journal of Medical Sciences (2011) 27, 85e90ava i lab le at www.sc iencedi rec t .com
journa l homepage : ht tp : / /www.k jms-on l ine .comORIGINAL ARTICLE
Incidence and associated risk factors of hepatocellular
carcinoma in a dural hepatitis B and C virus endemic area:
A surveillance study
肝癌高危險群之肝癌發生率及其相關因子：B、C型肝炎高盛行社區
研究Kuo-Chin Chang a,b, Sheng-Nan Lu a,b, Pao-Fei Chen a, Chao-Hung Hung a,b,
Kwong-Ming Kee a,b, Yi-Hao Yen a,b, Jing-Houng Wang a,b,*
張國欽 a,b, 盧勝男 a,b, 陳寶妃 a, 洪肇宏 a,b, 紀廣明 a,b, 顏毅豪 a,b, 王景弘 a,b,*aDivision of Hepato-Gastroenterology, Department of Internal Medicine, Chang Gung Memorial
Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
bChang Gung University College of Medicine, Kaohsiung, Taiwan
Received 7 July 2010; accepted 19 November 2010












上腹部超音波* Corresponding author. Division of H
Medical Center, 123, Ta Pei Road, Nia
E-mail address: jinghoung2001@ya
1607-551X/$36 Copyright ª 2011, Else
doi:10.1016/j.kjms.2010.11.001Abstract The purposes of this study were to determine the incidence of hepatocellular carci-
noma (HCC) in dual hepatitis B virus (HBV) and hepatitis C virus (HCV) endemic areas and to
assess the associated risk factors of HCC development in the community. During April 2004
to November 2005, 4,127 residents of Tainan County, aged 40 years or older, had participated
in a comprehensive health examination. Among them, residents with HBV or HCV infection;
platelet count less than or equal to 150 109/L; and no hepatic tumor, by liver ultrasonog-
raphy, were invited to this study. Alpha-fetoprotein (AFP) screening and ultrasonography for
HCC surveillance were performed. Once hepatic tumor was detected, the subjects were
referred to medical centers for further confirmation and treatment. A total of 1,133 residents
were eligible for this study, and 413 (36.5%), including 197 men and 216 women, with a mean
age of 64.5 years, were enrolled. There were 21 cases with suspected HCC. Of the 21 cases, 18
(85.7%) accepted further studies and 11 (52.4%) were confirmed to be affected with HCC. All
HCCs were unifocal with a diameter less than or equal to 4 cm. In the KaplaneMeier survival
analysis, the 2-year cumulative incidence of HCC was 4.7%. Based on the same analysis with
log rank test, AFP greater than or equal to 20 ng/mL (pZ 0.007), platelet count less than orepato-Gastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung
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86 K.-C. Chang et al.equal to 100 109/L (p< 0.001), and liver cirrhosis (p< 0.001) were found to be the associated
risk factors of HCC development. In summary, the 2-year cumulative incidence of HCC was
4.7% among adult residents with chronic HBV or HCV infection in this dual HBV and HCV
endemic area. Platelet count less than 100 109/L, AFP level greater than 20 ng/mL, and liver
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Hepatocellular carcinoma (HCC) is a malignant disease with
an increasing annual incidence globally [1]. Most of the
HCCs arise in the setting of liver cirrhosis (LC), and more
than 90% of the patients with HCC suffer from LC [2].
Hepatitis B virus (HBV) or hepatitis C virus (HCV) infections
are the two major causes of chronic hepatitis and LC, and
the annual incidence of HCC is between 1% and 8% in LC
patients [2]. With increasing knowledge of the risk factors
associated with HCC, surveillance programs have led to an
increase in the early identification of small HCCs that are
amenable to specific treatment options [3e5]. The benefits
of HCC surveillance have also been documented by cohort
studies and randomized control trials [3,4,6]. Therefore,
surveillance is extensively applied in clinical practice and is
recently recommended by the guidelines for HCC manage-
ment [1].
Previous studies have shown the benefit of serum
alpha-fetoprotein (AFP) screening for the early detection
of HCC [3,7]. However, its sensitivity and specificity were
poor [8]. The combination of AFP and ultrasonography
(US) screening improves the validity of HCC detection and
is the current standard surveillance tool [9]. Using serum
AFP and US screening, several hospital-based surveillance
studies in higher-risk individuals had demonstrated the
efficacy in the early detection of HCC, especially in high-
prevalence areas of chronic HBV or HCV infection
[10e14]. Although some community-based HCC screening
projects have been reported, community-based HCC
surveillance study is uncommon [4,15,16]. We conducted
the community-based surveillance study among high-risk-
group residents to determine the incidence and the risk
factors associated with HCC development in an HBV- and
HCV-endemic areas.Methods
Tainan County (southern Taiwan) with a population of
1,105, 674 people has been reported as an HBV- and HCV-
endemic area, with the prevalences of antibodies to HCV
(anti-HCV) and HBV surface antigen (HBsAg) being 10.2%
and 10.9%, respectively [17,18]. From April 2004 to
November 2005, Tainan County Health Bureau had con-
ducted a countywide community health screening,
including HBsAg, anti-HCV, AFP levels, aspartate amino-
transferase, alanine aminotransferase, platelet count, and
liver US, in six different locations of the county for resi-
dents who were older than 40 years. A total of 4,127 resi-
dents participated in this health screening.
Patients
Among the 4,127 residents, those with positive HBsAg or
anti-HCV; platelet count less than or equal to 150 109/L;
and no hepatic tumor, by liver US, were defined as
belonging to the high-risk group of HCC development and
were invited to this surveillance study. The study protocol
was approved by the Institutional Review Board of this
hospital and carried out in accordance with the Helsinki
declaration. The participating residents signed an informed
consent before entering this study. Surveillance US was
performed between May and August 2006.
Methods
All participants underwent liver US study and AFP-level
determination together with routine biochemical tests and
complete blood count. The determination of AFP level was
performed by means of microparticle enzyme immunoassay
Figure 1. Cumulative incidence of hepatocellular carcinoma
(HCC) in high-risk-group patients during surveillance.
Table 1 Factors associated with the development of HCC







Female 216 7 (3.2) 0.791
Male 197 4 (2.0)
Age (yr)
40e64 189 3 (1.6) 0.125
65 224 8 (3.6)
Village
Jian-gjium 52 3 (5.8) 0.062
Liouying 56 3 (5.4)
Houbi 54 2 (3.7)
Lioujia 102 2 (2.0)
Shiaying 98 1 (1.0)
Sinying 51 0 (0)
Viral marker
HBV 88 2 (2.3) 0.883
HCV 290 8 (2.8)
HBVþ HCV 35 1 (2.9)
AST/ALT
<1 244 6 (2.5) 0.247
1 169 5 (3.0)
Platelet count (109/L)
100 100 8 (8.0) <0.001
>100 313 3 (1.0)
AFP (ng/mL)
<20 390 8 (2.1) 0.006
20 23 3 (13)
Liver cirrhosis
Yes 154 11 (7.1) <0.001
No 259 0 (0)
AFPZ alpha-fetoprotein; ASTZ aspartate aminotransferase;
ALTZ alanine aminotransaminase; HBVZ hepatitis B virus;
HCCZ hepatocellular carcinoma; HCVZ hepatitis C virus.
HCC incidence in dual HBV and HCV area 87(MEIA) using a commercial kit (Abbott, IL, USA). Liver US
(Titan, Sonosite, Seattle, WA, USA) study was performed by
an experienced hepatologist. The subjects were referred to
medical centers for further confirmation and treatment if
hepatic focal lesion was detectable. Medical records were
abstracted from medical centers.
Statistics
The KaplaneMeier survival analysis was used to estimate
the cumulative probability of HCC development during the
surveillance period. Risk factors for HCC development were
evaluated by the KaplaneMeier survival, and log rank test
was used to compare the difference between the groups. A
value of p less than 0.05 was considered statistically
significant. Statistical analysis was performed with SPSS 10
for Windows (SPSS Inc., Chicago, IL, USA).
Results
A total of 1,133 eligible subjects were enrolled and invited
to this study. Of these residents, 720 patients failed to
attend US surveillance. Thus, 413 (36.5%) residents,
including 197 men and 216 women, with a mean age of 64.5
years, were enrolled in this study. HBsAg was positive in 88
residents and 290 were positive for anti-HCV. Both HBsAg
and anti-HCV were positive in 35 residents. The surveillance
interval ranged from 6 to 27 months.
Cumulative incidence and associated risk factors of
HCC development
Twenty-one residents were identified to have detectable
hepatic focal lesions, and 11 nodules were diagnosed as HCC.
HCC was confirmed histologically or cytologically in four
hepatic nodules and by typical dynamic imaging with an AFP
levelmore than400 ng/mL in sevennodules. ByKaplaneMeier
survival analysis, 11 patients developed HCC, and the cumu-
lative incidence of HCC development was 4.7% (Fig. 1) during
the study period. The following baseline features were
considered in relation to the risk factors of HCC development
in high-risk-group patients: age, sex, location of residence,
viral markers, aspartate aminotransferase/alanine amino-
transferase ratio, platelet count, AFP level, and LC (Table 1,
Fig. 2). The development of HCC was significantly higher in
high-risk patients with platelet count less than or equal to
100 109/L (p< 0.001), AFP greater than or equal to 20 ng/
mL (pZ 0.006), and LC (byUS) (p< 0.001). Further analysis of
risk factors of HCC development in high-risk patients with LC
and platelet count less than 100 109/L (pZ 0.018) is still
a significant risk factor (Table 2, Fig. 3).
HCC stage and treatment
All HCCs were single-nodule type, and the tumor size
ranged from 1 cm to 4 cm (mean standard deviation,
2.4 0.7 cm). According to Barcelona Clinic Liver Cancer
staging system for HCC, all of these patients were classified
as Stage 0 or A patients. The treatment modalities were
tumor resection (2 patients, 18.2%); percutaneous ethanol
injection or radiofrequency ablation (2 patients, 18.2%);
Figure 2. Cumulative incidence of hepatocellular carcinoma
(HCC) in high-risk-group patients in relation to (A) alpha-feto-
protein (AFP), (B) platelet count (PLT) during surveillance, and
(C) liver cirrhosis (LC).
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However, three patients refused to receive any treatment.
Discussion
The present study showed a cumulative incidence of 4.7% of
HCC development for high-risk group, defined as residents
with chronic HBV or HCV infection and low platelet count, in
this dual HBV- and HCV-endemic area. The platelet count less
than or equal to 100 109/L, high serum AFP levels (20 ng/
mL), and LC were the risk factors associated with HCC devel-
opment. Our surveillance program also shows that HCC can be
detected at a curative or palliative stage in most high-risk-
group patients in our population. We also found that platelet
count less than or equal to 100 109/L was a significant risk
factor relating to HCC development for the residents with LC.
The incidence of HCC is lower in cirrhotic or noncirrhotic
chronic HBV patients, that is, between 2.8% and 2.1% [11,12].
Hospital-based studies revealed a cumulative incidence
between 6.6% and 57.2% in cirrhotic patients [13,14]. In
contrast, the community-based studies revealed an incidence
of HCC between 0.3% and 5.3% [4,15,16], and the incidence is
found to be in the same range as in the present study. The
difference in the incidence of HCC reported by different
studies [4,11e16] may be because of several reasons. First, it
is not always clear if populations in different studies are
comparable. Hospital-based studies [10e14] would be
expected to include a high proportion of patients with
established cirrhosis, in whom the incidence of HCC would be
higher. On the other hand, population-based studies [4,15,16]
would beexpected tohavea lowerproportionof subjectswith
cirrhosis; hence, the expected incidence of HCC would be
lower. Another explanationmay be that the risk of HCC varies
in the protocols used to follow up, which was based on very
high titers of AFP (greater than 400 ng/mL), variability in the
frequency of screening, or differences in the follow-up
periods [13e15]. A previous study showed that the cumulative
incidence of HCC in patients with cirrhosis after 10 years was
57.2% [14]. In the present study, 11 HCCs were observed
among 413 patients in a follow-up period of 2 years, a rate
lower than that of the previous study [14].
It is generally accepted that a screening and surveillance
program is meant to detect early-stage tumors, to increase
the chance of receiving curative or palliative therapy, and to
reduce the HCC-related mortality rate [3,5,6,13]. Patients
with HCC detected by screening had less tumor burden, and it
might contribute to overall better survival. The present study
detected small tumors (mean size, 2.4 cm), and 72.8% of the
patients received curative or palliative treatment. Similar
results were also reported by a previous study in which the
subjects with HCC detected by screening were more likely to
haveoperableHCC [5]. Potentially curative treatment options
were performed in 36.4% of the patients in our study. There-
fore, this study showed that high-risk patients in the surveil-
lance program were in an earlier stage of HCC, which could
increase the chance of likelihood of receiving treatment.
HCC is a malignant tumor that, in most cases described
worldwide (even in high-incidence areas), occurred in
cirrhotic liver [1,2]. This supports the hypothesis that
cirrhosis per se, independent of etiology, is an important
oncogenic factor, as confirmed by data on the recurrence of
Table 2 Factors associated with developing HCC in high-risk-group patients with liver cirrhosis (nZ 154)
Variables High-risk cases, n HCC case, n (%) p
Sex
Female 88 7 (8.0) 0.671
Male 66 4 (6.1)
Age (yr)
40e64 65 3 (4.6) 0.157
65 89 8 (9.0)
Village
Jian-gjium 18 3 (16.7) 0.100
Liouying 21 3 (14.3)
Houbi 22 2 (9.1)
Lioujia 43 2 (4.7)
Shiaying 37 1 (2.7)
Sinying 13 0 (0)
Viral marker
HBV 26 2 (7.7) 0.760
HCV 115 8 (7)
HBVþ HCV 13 1 (7.7)
AST/ALT
<1 93 6 (6.5) 0.206
1 61 5 (8.2)
AFP (ng/mL)
<20 135 8 (5.9) 0.178
20 19 3 (15.8)
Platelet (109/L)
100 64 8 (14.3) 0.018
＞100 90 3 (3.2)
AFPZ alpha-fetoprotein; ASTZ aspartate aminotransferase; ALTZ alanine aminotransaminase; HBVZ hepatitis B virus; HCCZ he-
patocellular carcinoma; HCVZ hepatitis C virus.
HCC incidence in dual HBV and HCV area 89HCC after surgical resection. Some authors reported a rate
of recurrence between 75% and 100% [19]. Even a previous
study showed that HCC in normal liver is rare [20]. Among
the 360 individuals examined by US, only one case was
found to be without LC in our study. Thus, it suggested that
cirrhosis per se is important in the development of HCC.Figure 3. Cumulative incidence of hepatocellular carcinoma
(HCC) in high-risk-group patients with liver cirrhosis (LC) in
relation to thrombocytopenia during surveillance.We also found that an AFP level greater than or equal to
20 ng/mL at the time of diagnosis correlated with earlier
development of HCC. In some studies, a high basal level of
AFP has been associated with HCC [10,21]; notwithstanding
this, other study has not found an independent association
[22]. These contradictory results may be the result of the
differences in characteristics of patients with cirrhosis. A
previous report showed a level greater than 15 ng/mL in
10% of patients with virus-related LC and in only 0.7% of
patients with alcoholic cirrhosis [22]. This might imply that
the basal level of AFP possesses a predictive value for HCC
development only in patients with virus-related LC and not
in patients with nonviral cirrhosis.
Thrombocytopenia is frequently found in patients with
chronic liver disease and is associated with advanced
fibrosis with decreased liver function. Moreover, thrombo-
cytopenia is included as one of the risk factors for the
development of HCC [17,23e26]. In a hospital-based study,
changes in platelet counts were found to be a marker for
the risk of developing HCC in patients with HCV-related
cirrhosis [26]. The prevalence of thrombocytopenia in
individuals without chronic HBV or HCV infection was
approximately 5%, and thrombocytopenia was associated
strongly with HCV infection and was correlated with the
severity of liver disease in an HCV-endemic community in
Taiwan [23]. Results from another large-scale community
study also indicated an association among the prevalences
of anti-HCV and hypertransaminemia, thrombocytopenia,
and HCC [17]. In a previous study, thrombocytopenia was
90 K.-C. Chang et al.used as a surrogate marker, which showed 48% patients
with HBV- and HCV-related HCC [24]. Our study also showed
that thrombocytopenia was an associated risk factor in
developing HCC. The present study showed that 36.7%
patients had LC and 2.7% had HCC in the high-risk group
with thrombocytopenia. A previous study showed that 18%
of individuals in the high-endemic area and 6% of individ-
uals in the lower-endemic area had thrombocytopenia and
were identified as high-risk groups for US screening [25].
The platelet count is a cheap and simple surrogate marker
of cirrhosis and HCC. Thrombocytopenia should be
acceptable as a surrogate marker for the surveillance of
HCC, especially in patients with chronic HCV infection, in
the HBV- and HCV-endemic areas.
In conclusion, 2-year cumulative incidence of HCC
development was 4.7% among adult residents with chronic
HBV or HCV infection in this dual HBV- and HCV-endemic
area. Platelet count less than 100 109/L, AFP level
greater than 20 ng/mL, and LC were the associated risk
factors for HCC development. Surveillance for HCC by
thrombocytopenia and US screening can identify HCCs at an
early stage, resulting in a greater chance of receiving
effective treatment.
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